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O ver 480 000 percutaneous coronary interventions (PCIs) with intracoronary stent placement are performed annually in the United States. 1 Dual antiplatelet therapy (DAPT), consisting of aspirin and a P2Y 12 inhibitor, is the standard-of-care following PCI to prevent major adverse cardiovascular events (MACEs), including cardiovascular death, myocardial infarction, and stent thrombosis. 2 The Food and Drug Administration approved, orally administered P2Y 12 inhibitors in the United States include clopidogrel, prasugrel, and ticagrelor. Clopidogrel requires metabolism via the CYP (cytochrome P450) pathway to an active metabolite. It is well-established that patients carrying CYP2C19 lossof-function (LOF) alleles have a reduced capacity for clopidogrel bioactivation, impaired platelet inhibition, and a significantly higher risk of MACE when treated with clopidogrel compared with patients without a LOF allele. 3 In contrast, CYP2C19 genotype does not impact the clinical effectiveness of prasugrel or ticagrelor. 4, 5 Although use of CYP2C19 genotype to guide P2Y 12 inhibitor selection following PCI has been shown to improve clinical outcomes in several observational and smaller randomized studies, 6 large randomized trials comparing a genotyping strategy to conventional DAPT have not been completed, and the clinical benefits of this precision medicine approach remain controversial.
Overview of P2Y12 Inhibitor Pharmacology and Clinical Effects
Clopidogrel and prasugrel are thienopyridine prodrugs that undergo hepatic biotransformation by multiple CYP enzymes to generate their pharmacologically active metabolite that irreversibly inhibits the ADP P2Y 12 receptor. 3 Approximately 85% of clopidogrel is hydrolyzed by carboxylesterase-1, leaving only 15% available for active metabolite formation, which occurs predominantly by CYP2C19. Prasugrel is dependent on CYP3A4 and CYP2B6, and to a lesser extent CYP2C19, metabolism to form its active metabolite. Ticagrelor, a cyclopentyl-triazolopyrimidine, is a reversible, pharmacologically active, noncompetitive P2Y 12 inhibitor that is metabolized by CYP3A4 into a metabolite (AR-C124910XX) with equipotent antiplatelet effects.
Numerous studies have demonstrated substantial interpatient variability in platelet inhibition in those treated with clopidogrel. Clopidogrel nonresponse has been identified in 4% to 34% of patients, depending on the method of testing and the definition of response. 7 In contrast, prasugrel and ticagrelor exhibit more prompt, potent and consistent platelet inhibition compared with clopidogrel. 3 In the TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38) and PLATO (Study of Platelet Inhibition and Patient Outcomes) randomized trials, prasugrel and ticagrelor, respectively were superior to clopidogrel at reducing risk of MACE in acute coronary syndrome (ACS) patients, of which the majority underwent PCI (99% in TRITON-TIMI 38 and 61% in PLATO). 8, 9 However, prasugrel was associated with higher rates of major bleeding, and ticagrelor was associated with higher rates of noncoronary artery bypass graft surgery-related bleeding, and both have higher cost and discontinuation rates than clopidogrel. 10 As a result, clopidogrel remains the most commonly prescribed P2Y 12 inhibitor in clinical practice and accounted for over 50% of filled prescriptions following PCI in 2016. 10 The P2Y 12 inhibitor used in a specific patient is chosen based on clinical factors, such as indication for PCI, risk factors for bleeding, and economic considerations. Both pointof-care platelet function testing (PFT) and genotyping for CYP2C19 have been advocated as methods to more precisely select optimal antiplatelet therapy. VerifyNow is a point-ofcare test that measures platelet aggregation in response to ADP in patient blood samples. Results are measured as P2Y 12 reaction units, with lower values representing greater degrees of platelet inhibition. High on-treatment platelet reactivity (HPR) has been commonly defined as values >208 to 220 P2Y 12 reaction units. Despite early promising results from smaller studies, large randomized controlled trials failed to demonstrate a clinical benefit of using a PFT-guided approach to antiplatelet therapy. 11 For example, the ARCTIC trial (The Assessment by a Double Randomization of a Conventional Antiplatelet Strategy Versus a Monitoring-Guided Strategy for DrugEluting Stent Implantation and of Treatment Interruption Versus Continuation One Year After Stenting) randomized 2440 patients undergoing coronary stenting (27% with ACS) to conventional or PFT-guided therapy. 12 In the PFT-guided group, patients with HPR were given an additional loading dose of clopidogrel or prasugrel followed by maintenance therapy of double-dose clopidogrel (150 mg daily) or prasugrel (10 mg daily). In the conventional group, no PFT testing was performed, and treatment choice was left to the physician's discretion. This study found no significant difference in rates of the primary end point (composite of death, myocardial infarction, stent thrombosis, stroke, or urgent revascularization) or major bleeding between groups. Similar results were obtained from GRAVITAS trial (The Gauging Responsiveness with A VerifyNow assay-Impact on Thrombosis And Safety) that enrolled 2214 patients with HPR after treatment with aspirin and clopidogrel following PCI. 13 Patients were randomized to high-dose clopidogrel (150 mg daily) or standard-dose clopidogrel (75 mg daily) with results showing no difference in the incidence of MACE between the 2 groups. While these studies using PFT-guided dose escalation of clopidogrel were disappointing, interpretation of the results is limited by the use of 150 mg daily of clopidogrel in patients with HPR. The ELEVATE-TIMI 56 trial (Escalating Clopidogrel by Involving a Genetic Strategy-Thrombolysis in Myocardial Infarction 56) found that a clopidogrel dose of 225 mg daily in patients with one CYP2C19 LOF allele was necessary to obtain platelet inhibition that was similar to that observed with 75 mg daily of clopidogrel in patients without a LOF allele.
14 In patients with 2 LOF alleles, even doses as high as 300 mg daily of clopidogrel did not result in equivalent platelet inhibition.
CYP2C19 Genotype and Response to P2Y 12 Inhibitors Clopidogrel Response by CYP2C19 Genotype
Interpatient variability in clopidogrel response has been attributed to several factors, including variation in CYP2C19-mediated formation of clopidogrel's active metabolite. 15 Polymorphisms in CYP2C19 include LOF and increased function alleles, which combine to yield 5 CYP2C19 activity phenotypes: ultrarapid, rapid, normal, intermediate (IM), and poor (PM) metabolizers (Table) . 16 Approximately 30% of the US population carry either 1 or 2 LOF CYP2C19 alleles and are classified as IMs and PMs, respectively. 17, 18 The most common LOF alleles are CYP2C19*2 (rs4244285, c.681G>A, splicing defect) and CYP2C19*3 (rs4986893, c.636G>A, premature stop codon). 15 Other less common LOF alleles include CYP2C19*4, *5, *6, *7, and *8. A genome-wide association study of a healthy Amish population found that the CYP2C19*2 allele was the primary genetic locus associated with diminished platelet inhibitory response to clopidogrel and that the CYP2C19*2 allele accounted for 12% of the interpatient variability in platelet response to clopidogrel.
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CYP2C19 IMs and PMs have significantly lower plasma concentrations of the active metabolite and diminished inhibition of platelet aggregation compared with normal metabolizers. 19, 20 Retrospective analyses of patient registries and clinical trials have consistently shown that IMs and PMs treated with clopidogrel have an increased risk of adverse cardiovascular outcomes after PCI compared with those without a LOF allele. 4, [20] [21] [22] A meta-analysis of over 9000 clopidogreltreated patients reported a hazard ratio (HR) of 1.57 (95% CI, 1.13-2.16) for MACE and 2.81 (95% CI, 1.81-4.37) for stent thrombosis in IMs and PMs. 17 As a result, the US Food and Drug Administration added a black box warning to clopidogrel advising against use in PMs in 2010.
The diminished platelet inhibitory effect observed in IMs and PMs cannot be consistently or predictably overcome by increased doses of clopidogrel. 23 A meta-analysis of 10 960 patients with coronary artery disease demonstrated that despite use of high-dose clopidogrel (600/900 mg loading dose and 150 mg daily maintenance dose), CYP2C19*2 carriers had a higher risk of MACE (relative risk: 25 The genotype×treatment interaction (P=0.046) suggested that the overall efficacy benefit conferred by prasugrel over clopidogrel was driven in large part by the increased risk of MACE in CYP2C19 LOF allele carriers randomized to clopidogrel. Similarly, in a genetic substudy of PLATO, ticagrelor more prominently reduced MACE compared with clopidogrel in IMs and PMs (HR, 0.77; 95% CI, 0.60-0.99) than in those without a LOF allele (HR, 0.86; 95% CI, 0.74-1.01), although the genotype×treatment interaction was nonsignificant. 4 The ARCTIC-GENE substudy of the ARCTIC trial included 1394 patients who were retrospectively genotyped for the CYP2C19*2 LOF and *17 gain-offunction alleles. 26 Patients who were carriers of at least one LOF allele were more likely to have HPR but had similar clinical outcomes as patients without a LOF allele. Of note is that the primary treatment strategy for HPR was an escalation of clopidogrel dosing with <10% of patients with HPR treated with prasugrel at hospital discharge.
CYP2C19 Metabolizer Phenotypes by Geographic Region
CYP2C19 allele frequencies vary considerably across ethnic groups and geographic regions (Figure) . 18, 27 The average prevalence of IMs and PMs is similar throughout Africa, the Middle East, Europe, and the United States, with ≈30% of these populations carrying a LOF allele. However, the prevalence of IMs and PMs is markedly higher in Asian and Oceanian populations, with ≈57% and 94% of the population carrying a LOF allele, respectively. 18 There is evidence that the effect of LOF alleles may vary depending on ethnic population and indication for P2Y 12 inhibitors. A meta-analysis of 36 076 participants demonstrated that IMs and PMs in Asian populations who were undergoing PCI and prescribed clopidogrel had a higher risk of MACE relative to predominantly white populations. 28 Although the reasons for these underlying differences are unclear, these results and the high prevalence of LOF alleles suggest that genotype-guided antiplatelet therapy may offer particular clinical utility in populations with Asian ancestry.
Clinical Outcomes of Genotype-Guided Antiplatelet Therapy Post-PCI
Several recent studies conducted in China, the United States, and Europe have investigated the impact of CYP2C19 genotype-guided antiplatelet therapy on clinical outcomes ( Table  I in the online-only Data Supplement) and platelet reactivity (Table II in the online-only Data Supplement). These include multiple observational trials that found that genotype-guided therapy was superior to conventional therapy in patients undergoing PCI. A study of 628 PCI patients in China reported that genotype-guided therapy was associated with a lower risk of MACE at 12 months compared with conventional therapy (4.2% versus 9.4%; P=0.010) with no difference in bleeding. 29 An observational study conducted in Spain compared outcomes of a genotype-guided strategy to a historical control group that received conventional therapy. 30 The genotype-guided strategy recommended prasugrel or ticagrelor for IM/PMs and clopidogrel for non-IM/PMs and was associated with a lower risk of MACE (10.1% versus 14.1%; HR, 0.63; 95% CI, 0.41-0.97; P=0.037) and no difference in bleeding risk compared with conventional therapy. Finally, a study of 3260 Dutch patients undergoing elective PCI also reported that prasugrel was associated with a lower risk of MACE compared with clopidogrel in PM (5% versus 31%; P=0.003). 31 A study conducted in the United States by the Implementing Genomics in Practice Network represents the first large multicenter study to examine clinical outcomes of genotype-guided antiplatelet therapy. 22 The Implementing Genomics in Practice group examined outcomes in 1815 patients from 7 institutions in which CYP2C19 genetic testing was available for clinical use in PCI patients, and prasugrel or ticagrelor were recommended in IM/PMs. Prasugrel or ticagrelor was prescribed significantly more often in IM/PMs than non-IM/PMs (60.5% versus 15.5%; P<0.001). Use of clopidogrel was associated with a significantly higher risk of MACE in IM/PMs compared with alternative therapy during 12 months of follow-up (23.4 versus 8.7 per 100 patient-years; adjusted HR, 2.26; 95% CI, 1.18-4.32; P=0.013). Notably, the observed clinical benefit of genotype-guided antiplatelet therapy was driven by IMs, as ≈90% of PMs received alternative therapy, and was most pronounced in the strata of patients undergoing PCI for an ACS indication. A single-center retrospective analysis of 868 patients (572 of which were included in the Implementing Genomics in Practice analysis) also demonstrated a significantly higher risk of major adverse cardiovascular and cerebrovascular events in IM/PMs who received clopidogrel compared with alternative therapy and no difference in clinically significant bleeding events across groups. 32 Two small, randomized studies demonstrated superiority of genotype-guided DAPT. A single-center study from China of 600 patients undergoing PCI compared universal clopidogrel to genotype-guided therapy, which consisted of clopidogrel (75 mg daily) in non-IM/PMs, high-dose clopidogrel (150 mg daily) in IMs, and high-dose clopidogrel plus cilostazol in PMs. 33 At 180 days, genotype-guided therapy decreased risk of MACE compared with universal clopidogrel (2.7% versus 9.0%; P=0.001) with no difference in bleeding risk. Similar results were achieved in the PHARMCLO trial (Pharmacogenetics of Clopidogrel in Acute Coronary Syndromes), the largest randomized trial of genotype-guided antiplatelet therapy to date. 34 This Italian trial randomized 888 patients in 12 centers to either a standard-of-care or genotypeguided arm, which used a treatment algorithm that considered CYP2C19*2, CYP2C19*17, and ABCB1 c.3435C>T genotyping results but left ultimate therapy choice to provider discretion. Alternative therapy was prescribed significantly more often in the genotype-guided arm than the standard-of-care arm (50.2% versus 41.4%). Genotype-guided therapy conferred a significantly lower risk of cardiovascular death, myocardial infarction, stroke, or major bleeding compared with standard-of-care at 1 year (15.9% versus 25.9%; HR, 0.58; 95% CI, 0.43-0.78; P<0.001). This difference was driven by a lower risk of ischemic events, as there was no significant difference in major bleeding between groups.
Currently, 2 large, randomized trials that examine clinical outcomes are being conducted. The POPular Genetics (URL:
www.clinicaltrials.gov/ct2/show/NCT01761786. Unique identifier: NCT01761786) 35 and TAILOR-PCI (Tailored Antiplatelet Therapy Following PCI; URL: www. clinicaltrials.gov/ct2/show/NCT01742117. Unique identifier: NCT01742117) randomized controlled trials are comparing genotype-guided therapy, with prasugrel or ticagrelor prescribed in IMs and PMs, to conventional antiplatelet therapy. Popular genetics is enrolling ST-segment-elevation myocardial infarction patients undergoing PCI (n=2700), whereas the TAILOR-PCI trial includes either ACS or stable patients undergoing PCI (n=5270). Both studies are designed to assess major atherothrombotic and bleeding outcomes. These studies are expected to be completed in 2019 and 2020, respectively.
Effect of Indication on Genotype-Guided DAPT Outcomes
The largest benefit to genotype-guided DAPT seems to be in patients presenting with ACS who undergo PCI. In the Implementing Genomics in Practice study, the risk of MACE in patients with a LOF allele prescribed clopidogrel versus alternative therapy was 2.26× higher (95% CI, 1.18-4.32; P=0.013) in the group as a whole and 2.87× higher (95% CI, 1.35-6.09; P=0.013) in patients with ACS.
The relationship between CYP2C19 metabolizer status and clinical outcomes is less clear among clopidogrel-treated patients with coronary artery disease who are not undergoing PCI. In particular, there was no relationship between metabolizer status and the primary end point (a composite of cardiovascular death, recurrent myocardial infarction, or stroke at 30 months) in ACS patients who did not undergo PCI whether treated with prasugrel or clopidogrel in a large genetic substudy (n=5736 patients) of the TRILOGY-ACS trial (Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial).
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Clinical Relevance of Genetic Variants Beyond
CYP2C19 LOF Alleles
It remains unclear whether genetic variants beyond CYP2C19 LOF alleles are significantly associated with risk of MACE and bleeding events in clopidogrel-treated patients after PCI. The increased function CYP2C19*17 (rs12248560) allele, which increases CYP2C19 expression, is present in ≈30% of the US population. 15, 18 CYP2C19 rapid and ultrarapid metabolizers treated with clopidogrel exhibit increased active metabolite formation and inhibition of platelet aggregation, as well as higher bleeding risk and lower MACE risk in some, but not all, studies. 21, 37, 38 Because of inconsistent results and small number of patients studied compared with LOF alleles, the clinical implications for rapid and ultrarapid metabolizers remain uncertain.
Although ABCB1 c.3435C>T (decreased clopidogrel absorption) and carboxylesterase-1 (increased active metabolite formation) variant alleles are associated with clopidogrel pharmacokinetics and antiplatelet effects, these variants have yielded inconclusive effects on clinical outcomes, and testing for these variants is not currently recommended to guide clopidogrel prescribing. 15 Likewise, it remains unclear which, if any, genetic variants significantly impact the clinical and safety outcomes of prasugrel and ticagrelor. Although the CYP3A4*22 (rs35599367) and SLCO1B1 (rs4149056) alleles have recently been associated with higher ticagrelor plasma concentrations and antiplatelet effects, no associations with risk of MACE, bleeding, or dyspnea adverse events have been observed. Thus, additional studies are needed to determine whether these genetic variants, as well as those yet to be discovered, predict risk for atherothrombotic and bleeding events with DAPT after PCI. 18 Admixed Americas include data from studies conducted in North, Central, and South America.
Clinical Applications for Genotype-Guided Antiplatelet in Cerebrovascular Disease
CYP2C19 genotyping offers the potential to improve precision of antiplatelet therapy selection for cerebrovascular indications. A recent meta-analysis of 4762 patients with stroke or transient ischemic attack demonstrated that CYP2C19 IM/ PMs treated with clopidogrel had an increased risk of subsequent stroke events (12.0% versus 5.8%; RR, 1.92; 95% CI, 1.57-2.35; P<0.001), as well as the composite of total vascular events, compared with patients without a LOF allele.
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CYP2C19 genotyping may also have a role in neurointerventional procedures as a recent study found that CYP2C19 IM/ PMs prescribed clopidogrel had an increased risk of thromboembolism following neurointerventions. 40 
Conclusions
A growing body of evidence suggests that CYP2C19 genotype-guided antiplatelet therapy improves patient outcomes following PCI. Recent studies consistently demonstrate that a genotype-guided approach reduces risk of MACE in CYP2C19 IMs and PMs, which comprise ≈30% of the US population, without increasing bleeding risk. Similar associations may exist in patients with cerebrovascular indications for clopidogrel. The clinical feasibility and sustainability of CYP2C19 genotype-guided antiplatelet therapy in PCI patients has been demonstrated by a growing number of institutions, suggesting that this personalized medicine can be adapted into medical care delivery. The results of large, ongoing, randomized studies comparing a genotyping strategy to conventional DAP therapy offers the potential to change how DAPT is selected in cardiovascular patients.
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